SCIENTIFIC BASIS FOR INDIVIDUALIZATION AND OPTIMIZATION OF THERAPY FOR AIRBORNE DISEASES IN CHILDREN: A COMPREHENSIVE REVIEW

Abstract

Airborne diseases represent one of the most significant causes of morbidity and mortality in pediatric populations worldwide, imposing a substantial burden on healthcare systems. The conventional "one-size-fits-all" therapeutic approach to managing these infections, including pneumonia, bronchitis, influenza, and respiratory syncytial virus (RSV), is increasingly being challenged by the rise of antimicrobial resistance (AMR), high rates of treatment failure, and the potential for adverse drug reactions in children. The unique physiological and immunological characteristics of children, which undergo dynamic changes from infancy to adolescence, necessitate a more nuanced and personalized treatment strategy. This review article aims to provide a comprehensive scientific rationale for the individualization and optimization of therapy for airborne diseases in children. We explore the critical interplay of host factors (genetics, age-related pharmacokinetics/pharmacodynamics (PK/PD), immune status, microbiome) and pathogen characteristics (genotype, resistance patterns) in determining clinical outcomes. The paper synthesizes current evidence on advanced diagnostics, biomarker-guided therapies, pharmacogenomics, and therapeutic drug monitoring as key pillars for developing tailored treatment regimens. The central thesis is that a shift from empirical to precision-based therapy is not merely an academic pursuit but a clinical imperative to enhance therapeutic efficacy, minimize toxicity, and combat the growing threat of AMR. We discuss the integration of multi-omics data and computational modeling as future directions for creating dynamic, adaptive treatment protocols that can significantly improve the standard of care for children suffering from airborne infections.